Please assess the completion status of the following clinical trial:

Trial Title: Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years, all sexes.~* No previous hospitalizations in the last 6 months.~* Positive diagnostic test for COVID-19 according to the guidelines of the Argetine Ministry of Health at the time of enrollment.~* Patient in Intensive Care Unit with oxygen need: Need for continuous supply of oxygen to maintain saturation by oximetry pulse (SpO2) greater than or equal to 93% or arterial gas with PaO2 value greater than 60 mmHg~Exclusion Criteria:~* 18 years of age.~* Person unable to give consent.~* Person who refuses to participate.~* Pregnancy and lactation~* Participating in other study~* Requirement for mechanical ventilation.~* Inability to maintain prolonged sitting position (at least 2 hours)~* Subject with contraindications to HBOT (pulmonary shock, bullae, emphysema or untreated pneumothorax, severe seizures, uncontrolled hypertension, chronic obstructive disease of grade III or IV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental HBOT (Type: EXPERIMENTAL): Treatment (device). Patients will receive 90 minutes of hyperbaric oxygen at 1,45 ATA in a Revitalair430 hyperbaric chamber, and then they will continue with standard care and normobaric oxygen.
- Standard care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).